HC Wainwright Comments on Talphera FY2029 Earnings

Talphera, Inc. (NASDAQ:TLPH) – HC Wainwright issued their FY2029 earnings estimates for shares of Talphera in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst E. Arce forecasts that the company will earn $0.83 per share for the year. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Talphera’s current full-year earnings is ($0.64) per share.

Other equities research analysts have also issued research reports about the company. RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw began coverage on Talphera in a report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price target on the stock.

Talphera Trading Up 10.0 %

Shares of TLPH opened at $0.58 on Thursday. The firm’s fifty day simple moving average is $0.60 and its two-hundred day simple moving average is $0.71. Talphera has a 12 month low of $0.45 and a 12 month high of $1.27. The stock has a market capitalization of $9.93 million, a P/E ratio of -0.84 and a beta of 0.20.

Talphera (NASDAQ:TLPH) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.14.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.